CLINICAL RESEARCH: LIPID REDUCTION THERAPY
Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk PatientsThe MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial
Christie M. Ballantyne, MD, FACC*,*,
Joel S. Raichlen, MD, FACC and
Valerie A. Cain, MS
* Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas
Clinical Development, AstraZeneca, Wilmington, Delaware.
Manuscript received December 20, 2007;
revised manuscript received April 7, 2008,
accepted April 29, 2008.
* Reprint requests and correspondence: Dr. Christie M. Ballantyne, 6565 Fannin Street, MS A601, Suite A656, Houston, Texas 77030. (Email: cmb{at}bcm.edu).
Objectives: The purpose of this analysis was to compare concentrations of low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apoB) before and during statin therapy.
Background: Reducing LDL-C to a pre-determined goal may still leave an excess of atherogenic lipoproteins, as reflected in apoB levels.
Methods: The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial examined the effects of statin treatment in patients with high coronary heart disease (CHD) risk, LDL-C 130 and <250 mg/dl, and triglycerides <400 mg/dl. Therapy consisted of rosuvastatin (10 or 20 mg), atorvastatin (10 or 20 mg), or simvastatin (20 or 40 mg). The apoB and LDL-C or non–HDL-C at baseline and after 16 weeks of therapy were compared using linear regression.
Results: In untreated patients, the apoB target of <90 mg/dl was roughly equivalent to an LDL-C level <100 mg/dl and a non–HDL-C level <130 mg/dl, which is consistent with existing apoB and lipoprotein guidelines. However, during statin therapy, to reach an apoB target of <90 mg/dl it was necessary to reduce non–HDL-C to <100 mg/dl or to reduce LDL-C to <70 mg/dl (in high-triglyceride patients) or <80 mg/dl (in lower-triglyceride patients). The tight correlation seen for non–HDL-C with apoB while on statin therapy (R2 = 0.92) implies that non–HDL-C may be an acceptable surrogate for direct apoB measurement.
Conclusions: These data are consistent with the more aggressive cholesterol goals suggested for CHD patients, because achieving such targets also reduced apoB to the recommended level. (Mercury II–Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia; NCT00654407
[ClinicalTrials.gov]
)
Key Words: apolipoprotein B low-density lipoprotein cholesterol non–high-density lipoprotein cholesterol statins high-risk patients
|
Abbreviations and Acronyms
| | ACC = American College of Cardiology | | ADA = American Diabetes Association | | AHA = American Heart Association | | apoB = apolipoprotein B | | CHD = coronary heart disease | | HDL-C = high-density lipoprotein cholesterol | | LDL-C = low-density lipoprotein cholesterol | | TG = triglyceride |
|
Related Articles
-
Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients: Time for Revolutionary Changes?
- Yaakov Henkin
J. Am. Coll. Cardiol. 2008 52: 633-635.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A29-A30.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
H. Soran, M. W. France, S. Kwok, S. Dissanayake, V. Charlton-Menys, N. N. Younis, and P. N. Durrington
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients
Ann Clin Biochem,
November 1, 2011;
48(6):
566 - 571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Hermans and J.-C. Fruchart
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Therapeutic Advances in Chronic Disease,
September 1, 2011;
2(5):
307 - 323.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Jacobson
Opening a New Lipid "Apo-thecary": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk
Mayo Clin. Proc.,
August 1, 2011;
86(8):
762 - 780.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. V. Milani and C. J. Lavie
Another Step Forward in Refining Risk Stratification: Moving Past Low-Density Lipoprotein Cholesterol
J. Am. Coll. Cardiol.,
July 26, 2011;
58(5):
464 - 466.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Miller, N. J. Stone, C. Ballantyne, V. Bittner, M. H. Criqui, H. N. Ginsberg, A. C. Goldberg, W. J. Howard, M. S. Jacobson, P. M. Kris-Etherton, et al.
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Circulation,
May 24, 2011;
123(20):
2292 - 2333.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Olsson, C. Lindahl, I. Holme, R. Fayyad, O. Faergeman, J. J. Kastelein, M. J. Tikkanen, M. L. Larsen, T. R. Pedersen, and (on behalf of the Incremental Decrease in End Poin
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
European Journal of Cardiovascular Prevention & Rehabilitation,
April 1, 2011;
18(2):
262 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Lavie, R. V. Milani, and J. H. O'Keefe
Using Apolipoprotein B to Manage Dyslipidemia-Reply-II
Mayo Clin. Proc.,
August 1, 2010;
85(8):
771 - 772.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Lavie, R. V. Milani, and J. H. O'Keefe
To B or Not to B: Is Non-High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?
Mayo Clin. Proc.,
May 1, 2010;
85(5):
446 - 450.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Robinson
Are You Targeting Non-High-Density Lipoprotein Cholesterol?
J. Am. Coll. Cardiol.,
January 5, 2010;
55(1):
42 - 44.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. Knight, J. Yuan, S. Roy, and J. D. Imig
Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension
Am J Physiol Renal Physiol,
January 1, 2010;
298(1):
F86 - F94.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Rosenson, J. D. Otvos, and J. Hsia
Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study
Diabetes Care,
June 1, 2009;
32(6):
1087 - 1091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mora
Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use
Circulation,
May 5, 2009;
119(17):
2396 - 2404.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Zannad, P. Bousquet, and L. Monassier
CHAPTER 11 Clinical Pharmacology of Cardiovascular Drugs
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Henkin
Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients: Time for Revolutionary Changes?
J. Am. Coll. Cardiol.,
August 19, 2008;
52(8):
633 - 635.
[Full Text]
[PDF]
|
 |
|
|